PX-12

For research use only.

Catalog No.S7947 Synonyms: DB05448, 1-methyl propyl 2-imidazolyl disulfide

6 publications

PX-12 Chemical Structure

CAS No. 141400-58-0

PX-12 (DB05448, 1-methyl propyl 2-imidazolyl disulfide) is a potent thioredoxin-1 (Trx-1) inhibitor by irreversibly thioalkylation of Cys73 of Trx-1. Phase 2.

Selleck's PX-12 has been cited by 6 publications

Purity & Quality Control

Choose Selective Thioredoxin Inhibitors

Biological Activity

Description PX-12 (DB05448, 1-methyl propyl 2-imidazolyl disulfide) is a potent thioredoxin-1 (Trx-1) inhibitor by irreversibly thioalkylation of Cys73 of Trx-1. Phase 2.
Targets
Trx-1 [1]
()
In vitro

In MCF-7 and HT-29 cells, PX-12 prevents the hypoxia (1% oxygen)-induced increase in HIF-1alpha protein, and decreases HIF-1-trans-activating activity, VEGF formation, and inducible nitric oxide synthase. PX-12 also inhibits the growth of MCF-7 and HT-29 cells with IC50s of 1.9 μM and 2.9μM, respectively. [1] PX-12 also inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase. [2] In A549 cells, PX-12 inhibits cell growth via G2/M phase arrest, and Bax-mediated and ROS-dependent apoptosis. [3] In hepatocelluar carcinoma cells, PX-12 exerts a synergistic effect with 5-FU to significantly suppress tumorigenicity. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T84 NFLMTXBHfW6ldHnvckBie3OjeR?= MX2zJIhzew>? NHPFeppKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IITobY9z\WSxeHnuMY1m\GmjdHXkJHRIOiCjY4TpeoF1cW:wIHX4dJJme3OnZDDpckBVQDRiY3XscJMh[XO|ZYPz[YQh[XNiYnzvZ4ti\GVib3[gOU1jcW:2aX7hcYlld3CnboT5cIFucW6nIHnuZ49zeG:{YYTpc44h[W[2ZYKgN{BpenNiYomg[ox2d3Knc3PlcoNmKG2rY4Lvd4NweGmlIHHuZYx6e2m|LDDJR|UxRTJwMUJOwG0> NYnhN|JLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNlc3PTZpPkKzN|I4PjV4PD;hQi=>
MEF NGTGe4REgXSxdH;4bYNqfHliYYPzZZk> NHTUUlhEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBOTUZiY3XscJMtKEyGNUC9Nk44|ryP NXfBOJdpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxNlg5PzZpPkKyNVI5QDd4PD;hQi=>
Ramos NHjNSWxEgXSxdH;4bYNqfHliYYPzZZk> MYG3NkBpenN? NEHEcHlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBT[W2xczDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCOREWwQVMvPM7:TR?= MlHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzMki4O|YoRjJ{MUK4PFc3RC:jPh?=
PancO2 MkPMR5l1d3SxeHnjbZR6KGG|c3H5 NVjLbHNVPzJiaILz M4[wWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJHBidmORMjDj[YxteyCjZoTldkA4OiCqcoOgZpkh[3K7c4ThcEB3cW:uZYSgd5RicW6rbnesJGxFPTB;Mz65{txO MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF{OEi3Okc,OjJzMki4O|Y9N2F-
T24 NETDTo5EgXSxdH;4bYNqfHliYYPzZZk> NXXJZ5ZSPzJiaILz NVTjVmMyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXDJ2IHPlcIx{KGGodHXyJFczKGi{czDifUBkenm|dHHsJJZqd2yndDDzeIFqdmmwZzygUGQ2OD12LkdOwG0> NIPkU5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGyPFg4Pid-MkKxNlg5PzZ:L3G+
B78 M3XmWGN6fG:2b4jpZ4l1gSCjc4PhfS=> NFXmW3E4OiCqcoO= M3npc2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGI4QCClZXzsd{Bi\nSncjC3NkBpenNiYomgZ5J6e3SjbDD2bY9t\XRic4ThbY5qdmduIFzEOVA:Pc7:TR?= M3LpPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUK4PFc3Lz5{MkGyPFg4PjxxYU6=
CT26 MmK1R5l1d3SxeHnjbZR6KGG|c3H5 Mnj6O|IhcHK| MXrDfZRwfG:6aXPpeJkh[WejaX7zeEB4cWymIIT5dIUhdW:3c3WgR3QzPiClZXzsd{Bi\nSncjC3NkBpenNiYomgZ5J6e3SjbDD2bY9t\XRic4ThbY5qdmduIFzEOVA:PS5{zszN MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF{OEi3Okc,OjJzMki4O|Y9N2F-
K562 NHvhbINEgXSxdH;4bYNqfHliYYPzZZk> NI\ZOnQ4OiCqcoO= MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGxFPTB;NT61{txO NGjkNFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGyPFg4Pid-MkKxNlg5PzZ:L3G+
M21 M3jITWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M17nZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTUKxJINmdGy|LDDHTVUxRThwM988US=> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDVyMk[zPUc,OTh3MEK2N|k9N2F-
MCF7 MnGxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MnPZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3JINmdGy|LDDHTVUxRThwM988US=> Ml\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3MEK2N|koRjF6NUCyOlM6RC:jPh?=
MCF7 MmnFRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MYG0PEBpenN? NGO5cHBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJibXX0bI9lNCCJSUWwQVgvO87:TR?= NXTqVYtyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2NVc1OTRpPkG4OlE4PDF2PD;hQi=>
M21 M3jiW2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 MVW0PEBpenN? M3nWXmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTUKxJINmdGy|IHHmeIVzKDR6IHjyd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKG2ndHjv[EwhT0l3ME24MlPPxE1? M3fET|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkG3OFE1Lz5zOE[xO|QyPDxxYU6=
Raji M1yzXmN6fG:2b4jpZ4l1gSCjc4PhfS=> NYrjfoxEPzJiaILz MmTLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVoFrcSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBNTDVyPUiuPO69VQ>? NUHvc5VJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxNlg5PzZpPkKyNVI5QDd4PD;hQi=>
EMT6 NVnke3dWS3m2b4TvfIlkcXS7IHHzd4F6 M3jhdVczKGi{cx?= M4\YbGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGVOXDZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JINzgXO2YXygeolwdGW2IIP0ZYlvcW6pLDDMSFUxRTFzLkdOwG0> NFnVO5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGyPFg4Pid-MkKxNlg5PzZ:L3G+
HT29 MUXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWMkmgZ4VtdHNuIFfJOVA:OjYQvF2= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDVyMk[zPUc,OTh3MEK2N|k9N2F-
HT29 M374dWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MljZOFghcHK| NFz1cmRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUNlkh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJibXX0bI9lNCCJSUWwQVI2|ryP M37VTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkG3OFE1Lz5zOE[xO|QyPDxxYU6=
M21 Ml3iSpVv[3Srb36gZZN{[Xl? Ml\MNlUhdk1? M2rPbFE3KGi{cx?= NXHSe2dGW3SrbYXsZZRqd25ib3[gcpVkdGWjcjD0doFve2yxY3H0bY9vKG:oIITobY9z\WSxeHnuMVEh\nKxbTDjfZRwe2:uIHnuJIh2dWGwIF2yNUBk\WyuczDheEAzPSCwTTDh[pRmeiBzNjDodpMh[nliaX3teY5w[3m2b3\seY9z\XOlZX7j[S=> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZzN{SxOEc,OTh4MUe0NVQ9N2F-
Raji NYfmbY43TnWwY4Tpc44h[XO|YYm= MWG1JJRwKDFyIIXN MUG0JJRwKDJ2IHjydy=> NXuxT2FwUW6mdXP0bY9vKG:oIGTyfEBuWk6DIHX4dJJme3Orb36gbY4hcHWvYX6gVoFrcSClZXzsd{BifCB3IITvJFExKHWPIHHmeIVzKDRidH:gNlQhcHK|IHL5JHJVNVCFUjDhcoFtgXOrcx?= M3XnR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUK4PFc3Lz5{MkGyPFg4PjxxYU6=
Raji NX;CW3VQTnWwY4Tpc44h[XO|YYm= Mo\xNVAhfG9iMkCgeW0> NEHOPGE1KHSxIEigbJJ{ NY\qe4ZJUW6mdXP0bY9vKG:oIGTyfEBxem:2ZXnuJIV5eHKnc4Ppc44hcW5iaIXtZY4hWmGsaTDj[YxteyCjdDCxNEB1dyB{MDD1UUBi\nSncjC0JJRwKDhiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NGnNRW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGyPFg4Pid-MkKxNlg5PzZ:L3G+
DAOY MnHZdWhVWyCjc4PhfS=> M{DrN5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| MlLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 NW\0V5JseUiWUzDhd5NigQ>? NYjpXYtueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM> NFXDeJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
A673 MX7xTHRUKGG|c3H5 NHvlN3FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MmP0dWhVWyCjc4PhfS=> MVvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= NWHPTHhLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 M2LmTpFJXFNiYYPzZZk> NWnofZdFeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM> NF7CbWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 M2TsTpFJXFNiYYPzZZk> NH\nXWVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz NUDIOpNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 MYHxTHRUKGG|c3H5 M374ZpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= NGf1bm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 MVrxTHRUKGG|c3H5 Ml3zdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= M4C2TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD NXT0OZJqeUiWUzDhd5NigQ>? NYKye2dueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| MmiyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) NGrGUI1yUFSVIHHzd4F6 NUi5ZmdKeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 NGmyPHByUFSVIHHzd4F6 NV7WS|hkeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| MlHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC NH\DZVZyUFSVIHHzd4F6 NGfVNIJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy| NU\DR2s6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 MWfxTHRUKGG|c3H5 M4[zN5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTF{IHPlcIx{ NYPqbmFjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 NEXxVFdyUFSVIHHzd4F6 NWjEc5VPeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TC32 MXvxTHRUKGG|c3H5 NYDQdZZDeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN|MjDj[Yxtew>? NUfUPHpbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R) Mk[wdWhVWyCjc4PhfS=> Mn:zdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUWchPjNiKE[tWGchWiliY3XscJM> MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 Mn;ZdWhVWyCjc4PhfS=> M176dZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJM> Ml;pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH NXTzc5lqeUiWUzDhd5NigQ>? NY\yS4gxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= NXLWcXhnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>

... Click to View More Cell Line Experimental Data

In vivo In mice bearing MCF-7 tumor xenografts, PX-12 (12 mg/kg, i.p.) decreases HIF-1α and VEGF protein levels and microvessel density. [1]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: MCF-7 and HT-29 cells
  • Concentrations: ~10 μM
  • Incubation Time: 72 h
  • Method: Cell growth is measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cells are exposed to a range of concentrations of PX-12 or pleurotin for 16 h in air or hypoxia (1% oxygen). The cells are then washed with warm drug-free medium and grown in air for the remainder of the 72-h incubation.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Mice bearing MCF-7 tumor xenografts
  • Dosages: 12 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (201.79 mM)
Water Insoluble
Ethanol '38 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 188.31
Formula

C7H12N2S2

CAS No. 141400-58-0
Storage powder
in solvent
Synonyms DB05448, 1-methyl propyl 2-imidazolyl disulfide
Smiles CCC(C)SSC1=NC=CN1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00736372 Completed Drug: PX-12 Metastatic Cancer|Advanced Cancer Cascadian Therapeutics Inc.|Seagen Inc. June 2008 Phase 1
NCT00417287 Terminated Drug: PX-12 Pancreatic Neoplasms Cascadian Therapeutics Inc.|National Cancer Institute (NCI)|Translational Genomics Research Institute|Seagen Inc. December 2006 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy PX-12 | PX-12 supplier | purchase PX-12 | PX-12 cost | PX-12 manufacturer | order PX-12 | PX-12 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID